https://www.selleckchem.com/pr....oducts/gilteritinib-
ite the advanced age, we suggest favourable outcomes described in the absence of patients presenting with cardiogenic shock. Patients over the age of 80 who present with STEMI and undergo PPCI have a significantly lower mortality rate at 1 year. These patients have a 77.6% survival at 1 year, with 92.4% likelihood of discharge to home (without need for long-term nursing home care). Cardiogenic shock in this group was associated with a 1-year mortality of 87.5%. Despite the advanced age, we suggest favourable outcomes descri
Like
Comment
Share
